ECSP045310A - Material micronizado cristalino del bromuro de tiotropio - Google Patents

Material micronizado cristalino del bromuro de tiotropio

Info

Publication number
ECSP045310A
ECSP045310A EC2004005310A ECSP045310A ECSP045310A EC SP045310 A ECSP045310 A EC SP045310A EC 2004005310 A EC2004005310 A EC 2004005310A EC SP045310 A ECSP045310 A EC SP045310A EC SP045310 A ECSP045310 A EC SP045310A
Authority
EC
Ecuador
Prior art keywords
tiotrope
bromide material
crystalline micronized
preparation
micronized
Prior art date
Application number
EC2004005310A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045310A publication Critical patent/ECSP045310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hybrid Cells (AREA)

Abstract

El invento se refiere a un material micronizado cristalino de bromuro de (1a,2b,4b,5a,7b)-7-[(hidroxi-di-2-tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azonia-triciclo-[3.3.1.02,4]nonano, a procedimientos para su preparación así como a su utilización para la preparación de un medicamento, en particular para la preparación de un medicamento con efecto anticolinérgico.
EC2004005310A 2002-03-20 2004-09-23 Material micronizado cristalino del bromuro de tiotropio ECSP045310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
ECSP045310A true ECSP045310A (es) 2004-10-26

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005310A ECSP045310A (es) 2002-03-20 2004-09-23 Material micronizado cristalino del bromuro de tiotropio

Country Status (36)

Country Link
EP (3) EP1487832B9 (es)
JP (1) JP4331619B2 (es)
KR (2) KR101094091B1 (es)
CN (2) CN101220025A (es)
AR (1) AR039017A1 (es)
AT (1) ATE369365T1 (es)
AU (1) AU2003212327B2 (es)
BR (1) BRPI0308513B8 (es)
CA (1) CA2479652C (es)
CO (1) CO5611105A2 (es)
CY (2) CY1106923T1 (es)
DE (2) DE10212264A1 (es)
DK (2) DK1487832T4 (es)
EA (1) EA007064B1 (es)
EC (1) ECSP045310A (es)
ES (2) ES2291619T5 (es)
HR (1) HRP20040855B1 (es)
HU (1) HUE031876T2 (es)
IL (2) IL163841A0 (es)
LT (1) LT1785422T (es)
ME (1) ME02764B (es)
MX (1) MXPA04009056A (es)
MY (1) MY139720A (es)
NO (2) NO346754B1 (es)
NZ (1) NZ535808A (es)
PE (1) PE20030838A1 (es)
PL (1) PL220730B1 (es)
PT (2) PT1785422T (es)
RS (1) RS57551B1 (es)
SA (1) SA03240098B1 (es)
SI (1) SI1487832T2 (es)
TW (1) TWI345975B (es)
UA (1) UA78295C2 (es)
UY (1) UY27725A1 (es)
WO (1) WO2003078429A1 (es)
ZA (1) ZA200405636B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EA012326B1 (ru) 2003-11-03 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции
AU2004285685B2 (en) 2003-11-03 2011-03-24 Boehringer Ingelheim International Gmbh Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
EP2085396A3 (en) 2005-05-02 2009-11-25 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
KR20080007656A (ko) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 브로마이드의 신규한 결정질 형태
ES2530991T3 (es) 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
MX2007009988A (es) * 2005-12-19 2008-02-22 Sicor Inc Formas novedosas de bromuro de tiotropio y procesos para su preparacion.
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2533765A2 (en) * 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
EA036153B1 (ru) 2012-07-05 2020-10-06 Арвен Айлак Санайи Ве Тиджарет А.С. Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
PT3159277T (pt) * 2015-10-23 2019-09-11 Arven Ilac Sanayi Ve Ticaret As Blister para formulação inalável de brometo de tiotrópio
WO2017068119A1 (en) * 2015-10-23 2017-04-27 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
CA2347856C (en) * 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) † 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
JP2002542297A (ja) † 1999-04-23 2002-12-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 血管形成を増強するための治療組成物および方法
CA2387212A1 (en) 1999-10-12 2001-04-19 Kaken Pharmaceutical Co., Ltd. Dry powder inhalation and a method for the preparation thereof
IL149984A0 (en) 2000-10-12 2002-12-01 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
DK1326862T3 (da) 2000-10-12 2004-11-22 Boehringer Ingelheim Pharma Krystallinsk monohydrat af tiotropiumbromid, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
CA2450961C (en) 2001-06-22 2010-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244842B2 (en) 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
CY1118855T1 (el) 2018-01-10
EA007064B1 (ru) 2006-06-30
CN100368410C (zh) 2008-02-13
ES2291619T5 (es) 2018-12-07
EP1487832B9 (de) 2019-01-23
DE50307883D1 (de) 2007-09-20
PL220730B1 (pl) 2015-12-31
HRP20040855A2 (en) 2005-06-30
UY27725A1 (es) 2003-10-31
UA78295C2 (en) 2007-03-15
NO20044003L (no) 2004-10-14
BRPI0308513B1 (pt) 2016-04-19
LT1785422T (lt) 2017-02-10
WO2003078429A1 (de) 2003-09-25
ME02764B (me) 2011-05-10
JP4331619B2 (ja) 2009-09-16
MY139720A (en) 2009-10-30
JP2005526776A (ja) 2005-09-08
PE20030838A1 (es) 2003-11-21
SI1487832T2 (sl) 2018-11-30
MEP46708A (en) 2011-02-10
AR039017A1 (es) 2005-02-02
KR101021430B1 (ko) 2011-03-15
NO346754B1 (no) 2022-12-12
TWI345975B (en) 2011-08-01
TW200305421A (en) 2003-11-01
CA2479652A1 (en) 2003-09-25
PT1487832E (pt) 2007-08-27
KR20050008662A (ko) 2005-01-21
ZA200405636B (en) 2006-01-25
KR101094091B1 (ko) 2011-12-15
NZ535808A (en) 2005-09-30
ES2291619T3 (es) 2008-03-01
CA2479652C (en) 2012-07-10
SI1487832T1 (sl) 2007-12-31
EP3053921A1 (de) 2016-08-10
NO344427B1 (no) 2019-12-02
EP1785422B1 (de) 2016-11-16
HK1078871A1 (zh) 2006-03-24
EP1785422A8 (de) 2010-06-23
PT1785422T (pt) 2017-02-17
BR0308513A (pt) 2005-01-04
SA03240098B1 (ar) 2008-03-24
AU2003212327A1 (en) 2003-09-29
NO20190824A1 (no) 2004-10-14
EP1487832A1 (de) 2004-12-22
HRP20040855B1 (en) 2012-11-30
MXPA04009056A (es) 2005-01-25
CO5611105A2 (es) 2006-02-28
CN1642952A (zh) 2005-07-20
CY1106923T1 (el) 2012-09-26
ATE369365T1 (de) 2007-08-15
IL163841A0 (en) 2005-12-18
IL163841A (en) 2015-10-29
RS57551B1 (sr) 2018-10-31
DE10212264A1 (de) 2003-10-02
DK1487832T3 (da) 2007-11-05
EP1487832B2 (de) 2018-08-29
ES2615460T3 (es) 2017-06-07
EP1785422A1 (de) 2007-05-16
HUE031876T2 (en) 2017-08-28
KR20100135983A (ko) 2010-12-27
AU2003212327B2 (en) 2009-02-05
DK1785422T3 (en) 2017-02-27
DK1487832T4 (en) 2018-12-10
EP1487832B1 (de) 2007-08-08
CN101220025A (zh) 2008-07-16
BRPI0308513B8 (pt) 2021-05-25
EA200401142A1 (ru) 2005-04-28
PL371799A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
ECSP045310A (es) Material micronizado cristalino del bromuro de tiotropio
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
CR10327A (es) &#34;PIRIDIN(3-4-b) PIRAZINONAS&#34;
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
TW200626527A (en) Novel hexafluoroisopropanol derivatives
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
AR053775A1 (es) Nonadepsipeptidos acilados ii
SG165404A1 (en) Fulvestrant formulation
UY27670A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y de agentes inhibidores de la cinasa del egfr
PL1893237T3 (pl) Kompozycja farmaceutyczna zawierająca elastomer poliorganosiloksanowy i solubilizowany składnik aktywny
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
DOP2005000250A (es) Amidas de acido pirazindicarboxilico y su uso
CL2008002116A1 (es) Composicion farmaceutica compuesta por la combinacion de 25 a 500 mg de lamotrigina y 0.5 a 20 mg de clonazepam; y uso para el control y tratamiento de enfermedades tales como trastornos convulsivos, sindromes epilepticos y enfermedades relacionadas.